{"id":179344,"date":"2026-02-03T08:38:39","date_gmt":"2026-02-03T13:38:39","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=179344"},"modified":"2026-02-04T06:25:37","modified_gmt":"2026-02-04T11:25:37","slug":"mankind-pharma-q3-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/mankind-pharma-q3-fy26-earnings-results\/","title":{"rendered":"Mankind Pharma Q3 FY26 Earnings Results"},"content":{"rendered":"\n<p>Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.<\/p>\n\n\n\n<div style=\"height:35px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Q3 FY26 Earnings Results<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue from Operations:<\/strong> \u20b93,567 cr, +11.5% YoY (vs \u20b93,200+ cr last year) driven by strong domestic chronic portfolio demand.<\/li>\n\n\n\n<li><strong>EBITDA:<\/strong> \u20b9925 cr implied at 25.9% EBITDA margin expanded margins demonstrate operating leverage. <\/li>\n\n\n\n<li><strong>PAT:<\/strong> \u20b9410 cr, +7.7% YoY on improved demand and margin mix. <\/li>\n\n\n\n<li><strong>EPS:<\/strong> \u20b99.9.<\/li>\n\n\n\n<li><strong>Segments\/Geography:<\/strong> Domestic market share in chronic drugs improved to 39.3%; exports also grew in double-digits supporting topline. <\/li>\n<\/ul>\n\n\n\n<div style=\"height:36px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Management Commentary &amp; Strategic Decisions<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Management highlighted <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/740ea2bd-a613-4c62-b450-70ab75a552ed.pdf\" target=\"_blank\" rel=\"noopener\">robust demand for chronic therapy drugs<\/a> (cardiac and anti-diabetes), seen as the major revenue driver in Q3, suggesting sustained strength in high-growth therapeutic areas. <\/li>\n\n\n\n<li>EBITDA margin enhancement was attributed to cost efficiencies and improved mix focusing on higher-margin chronic and specialty products.<\/li>\n\n\n\n<li>Strategic initiatives around BSV integration and specialty portfolio expansion continue to support pipeline and future growth momentum.<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"839\" height=\"1024\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-36-839x1024.png\" alt=\"\" class=\"wp-image-179351\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-36-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-36-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-36-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-36-1259x1536.png 1259w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-36.png 1489w\" sizes=\"auto, (max-width: 839px) 100vw, 839px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Q2 FY26 Earnings Results<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue from Operations:<\/strong> \u20b93,697 cr, +20.8% YoY, strong year-on-year growth driven by chronic segment and BSV business consolidation. <\/li>\n\n\n\n<li><strong>EBITDA:<\/strong> \u20b9924 cr, 25% margin, reflecting solid profitability with scale. <\/li>\n\n\n\n<li><strong>PAT:<\/strong> \u20b9520 cr, -21% YoY (vs \u20b9661 cr in Q2 FY25), impacted by higher expenses and segment mix.<\/li>\n\n\n\n<li><strong>EPS:<\/strong> \u20b912.4 (diluted EPS). <\/li>\n<\/ul>\n\n\n\n<div style=\"height:32px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Management Commentary Q2<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Vice Chairman &amp; MD Rajeev Juneja attributed Q2 growth to outperformance in chronic therapies and BSV integration, though he acknowledged OTC segment pressure due to GST transition and weather impacts.<\/li>\n\n\n\n<li>Management reaffirmed confidence in long-term growth driven by four pillars: steady base business, specialty chronic portfolio, high-potential OTC, and BSV super-specialty offerings. <\/li>\n\n\n\n<li>Margin resilience and revenue diversification (domestic + exports) were highlighted as key strengths going forward. <\/li>\n<\/ul>\n\n\n\n<p>To view the company\u2019s previous earnings and latest concall transcripts,&nbsp;<a href=\"https:\/\/alphastreet.com\/india\/\">click here<\/a>&nbsp; to visit the Alphastreet India news channel.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products. Q3 FY26 Earnings Results Management Commentary &amp; Strategic Decisions Q2 FY26 Earnings Results Management Commentary Q2 To view the company\u2019s previous earnings and latest concall transcripts,&nbsp;click here&nbsp; to visit the Alphastreet [&hellip;]<\/p>\n","protected":false},"author":1863,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,5747],"tags":[10162],"class_list":["post-179344","post","type-post","status-publish","format-standard","hentry","category-infographics","category-healthcare-stocks","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":179008,"url":"https:\/\/alphastreet.com\/india\/sun-pharmaceutical-q3-fy26-earnings-results\/","url_meta":{"origin":179344,"position":0},"title":"Sun Pharmaceutical Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"February 2, 2026","format":false,"excerpt":"Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-17.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-17.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-17.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-17.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-17.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-17.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172230,"url":"https:\/\/alphastreet.com\/india\/mankind-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":179344,"position":1},"title":"Mankind Pharma Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 7, 2025","format":false,"excerpt":"Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products. \u00a0 Q2 FY26 Earnings Results Revenue from Operations: \u20b93,697.16 crore, up 20.77% YoY and 3.55% QoQ. EBITDA: \u20b9924 crore, with an EBITDA margin of 25.0%, representing\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Mankind Pharma Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Mankind-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Mankind-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Mankind-Pharma-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Mankind-Pharma-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Mankind-Pharma-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Mankind-Pharma-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170899,"url":"https:\/\/alphastreet.com\/india\/mankind-pharma-q1-fy26-earnings-results\/","url_meta":{"origin":179344,"position":2},"title":"Mankind Pharma Q1 FY26 Earnings Results","author":"Chirag Gupta","date":"September 3, 2025","format":false,"excerpt":"Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products. Presenting below are its Q1 FY26 earnings results. \u00a0 Q1 FY26 Earnings Results Consolidated Revenue: \u20b93,570.35 crores, up 24.4% YoY (Q1 FY25: \u20b92,867.85 crores). Profit After\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Mankind Pharma Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/6-1.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/6-1.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/6-1.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/6-1.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/6-1.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/6-1.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":178100,"url":"https:\/\/alphastreet.com\/india\/rpg-life-sciences-q3-fy26-earnings-results\/","url_meta":{"origin":179344,"position":3},"title":"RPG Life Sciences Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"January 28, 2026","format":false,"excerpt":"Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients. Q3 FY26 Earnings Results Revenue from Operations: \u20b9180.03 cr, +4.24% YoY vs \u20b9172.71 cr, \u22120.91% QoQ vs \u20b9181.68 cr. EBITDA: \u20b939.76 cr (PBDIT excl OI), +2% QoQ, margin 22.09% (+61 bps QoQ).\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-96.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-96.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-96.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-96.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-96.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-96.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":178005,"url":"https:\/\/alphastreet.com\/india\/sunteck-realty-q3-fy26-earnings-results\/","url_meta":{"origin":179344,"position":4},"title":"Sunteck Realty Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"January 28, 2026","format":false,"excerpt":"Sunteck Realty Limited is a Mumbai-based real estate developer focused on developing premium residential and commercial properties across Mumbai Metropolitan Region (MMR). Q3 FY26 Earnings Results Revenue from Operations: \u20b9344 cr, +113% YoY vs \u20b9162 cr, +71% QoQ. EBITDA: \u20b982 cr, +68% YoY, margin 24%. PAT: \u20b957 cr, +34% YoY\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":178529,"url":"https:\/\/alphastreet.com\/india\/usha-martin-q3-fy26-earnings-results\/","url_meta":{"origin":179344,"position":5},"title":"Usha Martin Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"January 30, 2026","format":false,"excerpt":"Usha Martin Ltd is primarily engaged in manufacture and sale of steel wires, strands, wire ropes, cords, related accessories, etc. It is also involved in sale of other products such as wire drawing and allied machines. Q3 FY26 Earnings Results Revenue from Operations: \u20b9917 cr, +6.6% YoY vs \u20b9861 cr,\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179344","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1863"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=179344"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179344\/revisions"}],"predecessor-version":[{"id":179352,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179344\/revisions\/179352"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=179344"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=179344"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=179344"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}